LBRX LB Pharmaceuticals Inc - Common Stock
NASDAQ · Pharmaceuticals · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 11, 2026
$36.99
· of 52w range
· above low
· to high
$14.3252w low
$50.1652w high
Market Cap (MRQ)
$1.06B
P/E
-11.8
EPS
$-3.13
your badges
52W Range
$14–$50
Analyst Rating
BUY
Price Target
$53
P/E
-11.8
ROE
-25.5%
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
LBRX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$36.99
Market Cap (MRQ)
$1.06B
P/E
-11.8
EPS
$-3.13
ROE
-25.5%
52W Range
$14–$50
LBRX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
EPS$-3.132024-12-31 → 2025-12-31
Free Cash Flow$-35M2025-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | LBRX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -11.8 | · | 12.9 | Overvalued | |
| P/B (MRQ) | 3.2 | · | 3.5 | Undervalued | |
| Price / FCF (TTM) | -12.8 | · | · | · | |
| Price / Cash Flow (TTM) | -12.9 | · | · | · | |
| Price / Tangible Book | 3.1 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | LBRX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| ROA | -14.5% | · | -0.47% | Weak | |
| ROE | -25.5% | · | -3.2% | Weak |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | LBRX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 15.1 | · | 2.3 | Strong liquidity | |
| Quick Ratio | 39.7 | · | 1.6 | Strong liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-31.7%
Next Report
Nov 04, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | $-1.71 | $-0.82 | -108.7% | |
| March 31, 2026 | $-0.67 | $-0.76 | 11.8% | |
| Dec. 31, 2025 | $-0.45 | $-0.46 | 1.4% | |
| Sept. 30, 2025 | $-0.61 | $-0.46 | -31.4% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| R&D Expense | $17M | $51M | |
| SG&A Expense | $14M | $14M | |
| Operating Expenses | $30M | $65M | |
| Interest Income | $4M | $2M | |
| Other Non-op | $5M | $2M | |
| Pretax Income | $-25M | $-63M | |
| Income Tax | $1.0K | $1.0K | |
| Net Income | $-25M | $-63M | |
| EPS (Basic) | $-3.13 | $-176.15 | |
| EPS (Diluted) | $-3.13 | $-176.15 | |
| Shares (Basic) | 8,045,145 | 358,229 | |
| Shares (Diluted) | 8,045,145 | 358,229 | |
| EBITDA | $321.0K | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Cash & Equivalents | $250M | $23M | |
| Short-term Investments | $45M | $5M | |
| Prepaid Expense | $13M | $880.0K | |
| Current Assets | $308M | $29M | |
| PP&E (Net) | $2M | $2M | |
| PP&E (Gross) | $2M | $2M | |
| Accum. Depreciation | $420.0K | $101.0K | |
| Total Assets | $313M | $34M | |
| Accounts Payable | $2M | $2M | |
| Accrued Liabilities | $5M | $5M | |
| Current Liabilities | $7M | $8M | |
| Capital Leases | $3M | $3M | |
| Total Liabilities | $12M | $14M | |
| Common Stock | $3.0K | $1.0K | |
| Retained Earnings | $-130M | $-104M | |
| AOCI | $168.0K | $111.0K | |
| Stockholders' Equity | $301M | $-95M | |
| Liabilities + Equity | $313M | $34M | |
| Shares Outstanding | 25,299,372 | 251,655 |
Cash Flow
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| D&A | $321.0K | $91.0K | |
| Stock-based Comp | $4M | $3M | |
| Deferred Tax | $0 | $0 | |
| Other Non-cash | $-15M | · | |
| Operating Cash Flow | $-35M | $-53M | |
| CapEx | $52.0K | $769.0K | |
| Investing Cash Flow | $-40M | $23M | |
| Financing Cash Flow | $303M | $38M | |
| Net Change in Cash | $227M | $8M | |
| Free Cash Flow | $-35M | · |
Profitability
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| ROA | -14.5% | · | |
| ROE | -25.5% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Current Ratio | 41.4 | · | |
| Quick Ratio | 39.7 | · |
Per Share
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Book Value / Share | $11.91 | · | |
| Cash Flow / Share | $-4.38 | · | |
| Cash / Share | $9.89 | · | |
| EPS (TTM) | $-3.13 | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Net Income TTM | $-25M | · | |
| Market Cap | $563M | · | |
| P/E | -7.1 | · | |
| P/B | 1.9 | · | |
| P / Tangible Book | 1.9 | · | |
| P / Cash Flow | -16.0 | · | |
| P / FCF | -16.0 | · | |
| Earnings Yield | -14.1% | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $44M | $15M | $8M | $2M | $2M | $3M | $376.0K | $11M | |
| SG&A Expense | $10M | $7M | $5M | $3M | $2M | $3M | $5M | $5M | |
| Operating Expenses | $54M | $22M | $14M | $5M | $5M | $6M | $6M | $16M | |
| Interest Income | $3M | $3M | $3M | $707.0K | $177.0K | $236.0K | $298.0K | $384.0K | |
| Other Non-op | $2M | $3M | $2M | $2M | $-12.0K | $1M | $469.0K | $2M | |
| Pretax Income | $-52M | $-19M | $-11M | $-4M | $-5M | $-5M | $-5M | $-14M | |
| Income Tax | $0 | $0 | $1.0K | $0 | $0 | $0 | $1.0K | $0 | |
| Net Income | $-52M | $-19M | $-11M | $-4M | $-5M | $-5M | $-5M | $-14M | |
| EPS (Basic) | $-1.71 | $-0.67 | $3.13 | $-0.61 | $-13.58 | $-14.79 | $-14.00 | $-39.49 | |
| EPS (Diluted) | $-1.71 | $-0.67 | $3.13 | $-0.61 | $-13.58 | $-14.79 | $-14.00 | $-39.49 | |
| Shares (Basic) | 30,137,733 | 28,241,701 | · | 5,806,862 | 358,811 | 358,777 | · | 359,079 | |
| Shares (Diluted) | 30,137,733 | 28,241,701 | · | 5,806,862 | 358,811 | 358,777 | · | 359,079 |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $283M | $321M | $250M | $270M | · | · | $23M | · | |
| Short-term Investments | $45M | $45M | $45M | $45M | · | · | $5M | · | |
| Prepaid Expense | $28M | $23M | $13M | $2M | · | · | $880.0K | · | |
| Current Assets | $355M | $389M | $308M | $316M | · | · | $29M | · | |
| PP&E (Net) | $2M | $2M | $2M | $2M | · | · | $2M | · | |
| PP&E (Gross) | $3M | $2M | $2M | $2M | · | · | $2M | · | |
| Accum. Depreciation | $599.0K | $502.0K | $420.0K | $337.0K | · | · | $101.0K | · | |
| Total Assets | $362M | $393M | $313M | $321M | · | · | $34M | · | |
| Accounts Payable | $3M | $7M | $2M | $3M | · | · | $2M | · | |
| Accrued Liabilities | $19M | $3M | $5M | $3M | · | · | $5M | · | |
| Current Liabilities | $24M | $11M | $7M | $7M | · | · | $8M | · | |
| Capital Leases | $4M | $3M | $3M | $3M | · | · | $3M | · | |
| Total Liabilities | $29M | $15M | $12M | $11M | · | · | $14M | · | |
| Common Stock | $3.0K | $3.0K | $3.0K | $3.0K | · | · | $1.0K | · | |
| Retained Earnings | $-200M | $-149M | $-130M | $-118M | · | · | $-104M | · | |
| AOCI | $186.0K | $208.0K | $168.0K | $-53.0K | · | · | $111.0K | · | |
| Stockholders' Equity | $332M | $379M | $301M | $310M | · | · | $-95M | · | |
| Liabilities + Equity | $362M | $393M | $313M | $321M | · | · | $34M | · | |
| Shares Outstanding | 28,681,063 | 28,674,827 | 25,299,372 | 25,299,102 | · | · | 251,655 | · |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $5M | $3M | $2M | $881.0K | $335.0K | $634.0K | $2M | · | |
| Operating Cash Flow | $-38M | $-23M | $-18M | $-3M | $-6M | $-8M | $-6M | · | |
| CapEx | $363.0K | $32.0K | $40.0K | $0 | $-9.0K | $21.0K | $238.0K | · | |
| Investing Cash Flow | $89.0K | $-32.0K | $-40.0K | $-45M | $9.0K | $5M | $14M | · | |
| Financing Cash Flow | $-19.0K | $94M | $-1M | $304M | $0 | $0 | $0 | · | |
| Net Change in Cash | $-38M | $71M | $-19M | $256M | $-6M | $-3M | $8M | · | |
| Free Cash Flow | · | $-23M | · | · | · | · | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|---|
| ROA | -28.5% | -9.7% | · | -2.2% | · | · | · | · | |
| ROE | -31.1% | -10.1% | · | -2.3% | · | · | · | · |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.1 | 35.7 | · | 47.6 | · | · | · | · | |
| Quick Ratio | 13.9 | 33.5 | · | 47.3 | · | · | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $11.59 | $13.21 | · | $12.26 | · | · | · | · | |
| Cash Flow / Share | · | $-0.82 | · | · | · | · | · | · | |
| Cash / Share | $9.87 | $11.18 | · | $10.66 | · | · | · | · | |
| EPS (TTM) | $0.14 | $-11.73 | · | $-42.98 | $-81.86 | · | · | · |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-86M | $-39M | · | $-19M | $-29M | $-52M | · | · | |
| Market Cap | $931M | $707M | · | $399M | · | · | · | · | |
| P/E | 231.8 | -2.1 | · | -0.4 | · | · | · | · | |
| P/B | 2.8 | 1.9 | · | 1.3 | · | · | · | · | |
| P / Tangible Book | 2.8 | 1.9 | · | 1.3 | · | · | · | · | |
| P / Cash Flow | · | -30.4 | · | · | · | · | · | · | |
| Earnings Yield | 0.43% | -47.6% | · | -272.2% | · | · | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Income | $-25M | $-63M |
| Diluted EPS | $-3.13 | $-176.15 |
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Current Ratio | 41.4 | · |
| Quick Ratio | 39.7 | · |
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free Cash Flow | $-35M | · |
Institutional owners (13F) 118 filers · $990.7M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
118
Value held
$990.7M
New positions
43
Exited positions
3
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 43 (+23 vs prior Q) | 3 (-7 vs prior Q) | 39 (+8 vs prior Q) | 13 (+1 vs prior Q) | +1.7M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| Deep Track Capital, LP | $108,815,254 | 3,352,804 | 10.98% | Shares |
| BlackRock, Inc. | $88,741,868 | 2,734,305 | 8.96% | Shares |
| RA CAPITAL MANAGEMENT, L.P. | $71,680,243 | 2,208,604 | 7.24% | Shares |
| Trails Edge Capital Partners, LP | $49,429,679 | 1,523,022 | 4.99% | Shares |
| JPMORGAN CHASE & CO | $48,871,644 | 1,497,293 | 4.93% | Shares |
| Commodore Capital LP | $48,682,500 | 1,500,000 | 4.91% | Shares |
| TCG Crossover Management, LLC | $46,972,446 | 1,447,310 | 4.74% | Shares |
| Caligan Partners LP | $46,672,562 | 1,438,070 | 4.71% | Shares |
| Spruce Street Capital LP | $44,663,240 | 1,376,159 | 4.51% | Shares |
| Nantahala Capital Management, LLC | $34,171,675 | 1,052,894 | 3.45% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $31,519,160 | 971,165 | 3.18% | Shares |
| Balyasny Asset Management L.P. | $29,906,341 | 921,471 | 3.02% | Shares |
| Alyeska Investment Group, L.P. | $28,039,400 | 863,947 | 2.83% | Shares |
| Vivo Capital, LLC | $25,964,000 | 800,000 | 2.62% | Shares |
| VANGUARD GROUP INC | $24,774,891 | 1,112,978 | 2.50% | Shares |
| Nan Fung Group Holdings Ltd | $20,467,973 | 630,657 | 2.07% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $19,893,259 | 612,793 | 2.01% | Shares |
| STATE STREET CORP | $19,538,819 | 602,028 | 1.97% | Shares |
| Logos Global Management LP | $18,986,175 | 585,000 | 1.92% | Shares |
| GOLDMAN SACHS GROUP INC | $18,708,879 | 576,456 | 1.89% | Shares |
| JENNISON ASSOCIATES LLC | $17,554,973 | 540,902 | 1.77% | Shares |
| GREAT POINT PARTNERS LLC | $10,295,408 | 317,221 | 1.04% | Shares |
| BOOTHBAY FUND MANAGEMENT, LLC | $8,947,032 | 275,675 | 0.90% | Shares |
| MILLENNIUM MANAGEMENT LLC | $8,412,953 | 259,219 | 0.85% | Shares |
| AMERIPRISE FINANCIAL INC | $7,383,026 | 227,485 | 0.75% | Shares |
| CITADEL ADVISORS LLC | $7,009,274 | 215,969 | 0.71% | Shares |
| HighVista Strategies LLC | $6,864,590 | 211,511 | 0.69% | Shares |
| BAKER BROS. ADVISORS LP | $6,491,000 | 200,000 | 0.66% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $6,344,498 | 195,486 | 0.64% | Shares |
| FMR LLC | $6,130,990 | 188,907 | 0.62% | Shares |
| NORTHERN TRUST CORP | $6,037,831 | 186,037 | 0.61% | Shares |
| Eversept Partners, LP | $5,960,783 | 183,663 | 0.60% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $5,283,706 | 162,801 | 0.53% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $4,938,418 | 152,162 | 0.50% | Shares |
| Integral Health Asset Management, LLC | $4,868,250 | 150,000 | 0.49% | Shares |
| RAYMOND JAMES FINANCIAL INC | $2,974,695 | 91,656 | 0.30% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $2,803,171 | 86,371 | 0.28% | Shares |
| UBS Group AG | $2,789,539 | 85,951 | 0.28% | Shares |
| Longbow Finance SA | $2,672,215 | 82,336 | 0.27% | Shares |
| Boxer Capital Management, LLC | $2,271,850 | 70,000 | 0.23% | Shares |
| NEXTBio Capital Management LP | $2,215,021 | 68,249 | 0.22% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $1,911,308 | 58,891 | 0.19% | Shares |
| Bank of New York Mellon Corp | $1,784,343 | 54,979 | 0.18% | Shares |
| ALERUS FINANCIAL NA | $1,781,487 | 54,891 | 0.18% | Shares |
| Nuveen, LLC | $1,692,269 | 52,142 | 0.17% | Shares |
| MORGAN STANLEY | $1,661,922 | 51,207 | 0.17% | Shares |
| JANUS HENDERSON GROUP PLC | $1,613,479 | 65,429 | 0.16% | Shares |
| TWO SIGMA INVESTMENTS, LP | $1,579,001 | 48,652 | 0.16% | Shares |
| XTX Topco Ltd | $1,525,580 | 47,006 | 0.15% | Shares |
| Y-Intercept (Hong Kong) Ltd | $1,279,149 | 39,413 | 0.13% | Shares |
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Deep Track Biotechnology Master Fund, Ltd., Deep Track Special Opportunities Fund, LP, Deep Track Capital, LP, David Kroin ×2 filings | Feb. 10, 2026 | 0.00% | Amendment | · | SEC |
| Pontifax Management 4 G.P. (2015) Ltd., Pontifax VI G.P. L.P., Ran Nussbaum, Tomer Kariv | Sept. 25, 2025 | 6.30% | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 15 insiders · 5 officers · 9 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Heather D Turner | Chief Executive Officer | Sept. 10, 2025 A | · | 0 | 0 | $0 |
| Panandiker Kaya Kamlesh Pai | Chief Commercial Officer | Dec. 10, 2025 A | · | 0 | 0 | $0 |
| Richard Anthony Silva | SVP, Technical Operations | Sept. 10, 2025 A | · | 0 | 0 | $0 |
| Anna Eramo | Chief Medical Officer | Sept. 10, 2025 A | · | 0 | 0 | $0 |
| Gad Soffer | Chief Business Officer | Sept. 10, 2025 A | · | 0 | 0 | $0 |
| Rebecca Luse | Director | June 3, 2026 A | · | 0 | 0 | $0 |
| Robert A. Lenz | Director | June 3, 2026 A | · | 0 | 0 | $0 |
| William P Kane Jr | Director | June 3, 2026 A | · | 0 | 0 | $0 |
| Rekha Hemrajani | Director | June 3, 2026 A | · | 0 | 0 | $0 |
| Ran Nussbaum | Director | June 3, 2026 A | 1,411,681 | 0 | 0 | $0 |
| Scott J. Garland | Director | June 3, 2026 A | · | 0 | 0 | $0 |
| Robert R Ruffolo | Director | June 3, 2026 A | · | 0 | 0 | $0 |
| Zachary Prensky | Director | Sept. 10, 2025 A | · | 0 | 0 | $0 |
| Pontifax Management 4 GP (2015) Ltd. | 10% owner | Sept. 12, 2025 C | 1,411,681 | 0 | 0 | $0 |
| Marc L Panoff | · | Sept. 10, 2025 A | · | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 21 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| IBRN · iShares Trust | 1.01% | 1,628 SH | Sept. 11, 2026 | Daily |
| BBC · ETFis Series Trust I | 0.94% | 10,936 NS | July 31, 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 0.73% | 3,779 NS | July 31, 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0.56% | 1,258 NS | July 31, 2026 | N-PORT |
| IHE · iShares Trust | 0.26% | 90,080 SH | Sept. 11, 2026 | Daily |
| IWC · iShares Trust | 0.24% | 76,018 SH | Sept. 11, 2026 | Daily |
| IWM · iShares Trust | 0.03% | 576,210 SH | Sept. 11, 2026 | Daily |
| IWO · iShares Trust | 0.03% | 99,716 SH | Sept. 11, 2026 | Daily |
| RSSL · Global X Funds | 0.03% | 10,682 NS | July 31, 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.02% | 128,900 SH | Aug. 19, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.02% | 10,246 SH | Aug. 19, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.02% | 11,382 SH | Aug. 19, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 278,799 SH | Aug. 19, 2026 | Daily |
| FHLC · FIDELITY COVINGTON TRUST | 0.01% | 7,157 NS | July 31, 2026 | N-PORT |
| WSML · iShares Trust | 0.01% | 1,005 SH | Sept. 11, 2026 | Daily |
| ITOT · iShares Trust | 0.00% | 36,244 SH | Sept. 11, 2026 | Daily |
| IWV · iShares Trust | 0.00% | 6,315 SH | Sept. 11, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 672,000 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 1,634 SH | Aug. 19, 2026 | Daily |
| IWN · iShares Trust | · | 110,981 SH | Sept. 11, 2026 | Daily |
| ISCB · iShares Trust | · | 815 SH | Sept. 11, 2026 | Daily |
LBRX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 15 analysts
BUY
Median target
$53.50
+44.6%
5 33.3%
Strong Buy
9 60.0%
Buy
1 6.7%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
8 analysts · 2026-10-02Mean target $53.38 +44.3%
← Below all targets
Current price $36.99
Low$37.00
Mean$53.38
High$78.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| LBRX | $563M | -7.1 | · | · | -25.5% | · |
| MAZE | $2.04B | -13.6 | · | · | -598.9% | · |
| XERS | $1.30B | · | 43.7% | 0.19% | -19.7% | · |
| KARD | · | · | · | · | · | · |
| OMER | $1.23B | -343.6 | · | · | 1.9% | · |
| AVLN | · | · | · | · | · | · |
| HROW | $1.82B | -350.0 | 36.4% | -1.9% | -8.4% | 75.0% |
| YARW | · | · | · | · | · | · |
| AMPH | $1.22B | 13.2 | -1.7% | 13.6% | 12.7% | 49.5% |
| PCRX | $1.06B | 161.8 | 3.6% | 0.97% | 0.97% | · |
| LLY | · | 46.8 | 44.7% | 31.7% | 101.2% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 11, 2026